The article by Nghiem-Buffet et al 1 evaluated ophthalmology and treatment visits for ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) and dexamethasone (Ozurdex; Allergan, Irvine ...

Outside the U.S., Lucentis is approved in more than 110 countries to treat patients with wet AMD, for the treatment of DME, and due to macular edema secondary to both branch retinal vein occlusion ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...

3) RVO duration between 6 weeks to 9 months. 4) CFT ≥ 250 μm RCT = prospective randomized controlled; RVO = retinal vein occlusion; IVR = intravitreal ranibizumab; M = multicenter; CRVO = central ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

Lucentis (ranibizumab) is a prescription drug that’s used for eye conditions such as macular edema. Lucentis comes as a liquid solution that’s given by injection into the eye. Lucentis is prescribed ...

The common therapies for CRVO treatment are laser photocoagulation for peripheral ischemia, macular laser for ME (occasionally) and intravitreal injections of anti-VEGF and steroids, which are used to ...

NEW YORK, July 13, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, today announced positive final results from a Phase II investigator ...

At 2 years, Black and white patients who received Lucentis for the treatment of diabetic macular edema achieved similar ...

Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated ...